Skip to main content
OpenTrials
Completed

NCT Number: NCT00544921

Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Univ FL

Gainesville, Florida, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men age 18-55
  • Negative drug screen
  • Normal EKG, clinical chemistries, CBC, urinalysis, and
  • Give written informed consent

Exclusion criteria

  • Active concomitant serious medical or surgical disease,
  • Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days

Treatment and study plan

GLY-230

Drug

Placebo

Other

No drug administered

Primary outcomes

  1. A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects

    Time frame: October, 2005 to October, 2006

Sponsors and collaborators

Lead sponsor

Glycadia

Industry

Collaborators

  • University of Florida

Registry information

Official study title

Phase 1 Study of Anti-glycation Agent GLY-230

Important dates

Study start
2005
Primary completion
2006
Study completion
2006
First posted
Oct 16, 2007
Registry last updated
Feb 10, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.